<DOC>
	<DOCNO>NCT02515539</DOCNO>
	<brief_summary>The purpose study generate early US feasibility data CardiAQ™ Transcatheter Mitral Valve Implant System . The study enroll patient moderate severe mitral valve regurgitation consider high risk mortality morbidity conventional open-heart surgery .</brief_summary>
	<brief_title>Early Feasibility Study CardiAQ™ TMVI System ( Transfemoral Transapical DS )</brief_title>
	<detailed_description>Early feasibility study - multi-center , prospective , single-arm , non-randomized study without concurrent historical control . The primary objective study generate early feasibility data CardiAQ™ Transcatheter Mitral Valve Implant System Transfemoral Transapical Delivery Systems treatment moderate severe mitral valve regurgitation patient consider high risk mortality morbidity conventional open-heart surgery . The secondary objective study evaluate long-term safety device effect device performance , functional , quality life parameter , technical , device , procedural , individual patient success . The study perform maximum 5 investigational site US .</detailed_description>
	<mesh_term>Cardiovascular Diseases</mesh_term>
	<mesh_term>Heart Diseases</mesh_term>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Key NYHA Classification ≥ III Left Ventricular Ejection Fraction ≥ 30 % Mitral Regurgitation ≥ Grade 3+ Subject meet anatomical eligibility criterion investigational device See Protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Transcatheter Mitral Valve Replacement</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Mitral Insufficiency</keyword>
	<keyword>Transapical</keyword>
	<keyword>Transfemoral</keyword>
</DOC>